This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
The Zacks Analyst Blog Highlights: CommScope, Incyte, Cigna, Columbia Sportswear and Synopsys
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CommScope, Incyte, Cigna, Columbia Sportswear and Synopsys
What's in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.
Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?
by Zacks Equity Research
During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.
5 Biotech Stocks Defying the Medicare-for-All Scare
by Swarup Gupta
Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.
Can S&P 500 and Nasdaq Sustain Record Run? 5 Top Picks
by Nalak Das
The broad-market S&P 500 Index and tech-laden Nasdaq Composite closed at an all-time high level yesterday.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on sales growth.
What's in the Cards for AstraZeneca (AZN) in Q1 Earnings?
by Zacks Equity Research
AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.
5 Must-Buy Stocks Amid Exaggerated Economic Slowdown
by Nalak Das
The recently released three major economic data of March clearly indicated that the inherent strength of the economy remains intact.
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group
by Zacks Equity Research
Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Concert Pharma Initiates Early-Stage Schizophrenia Study
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.
4 Toxic Stocks to Abandon or Sell Short for Solid Gains
by Zacks Equity Research
Overpriced toxic stocks are generally susceptible to outside shocks and burdened with a huge amount of debt.
Why Is Incyte (INCY) Up 1.7% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica
10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run
by Sweta Killa
Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.
4 Toxic Stocks to Abandon or Sell Short for Solid Gains
by Zacks Equity Research
Overhyped toxic stocks are usually susceptible to external shocks and burdened with huge amount of debt.
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda
by Zacks Equity Research
Merck (MRK) gets CHMP recommendation for a six-week dosing schedule of Keytruda across all current monotherapy indications.
Zacks.com featured expert Kevin Matras highlights: First Majestic Silver, Incyte, Covanta and U.S. Silica
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: First Majestic Silver, Incyte, Covanta and U.S. Silica
4 Toxic Stocks to Discard or Sell Short for Solid Gains
by Zacks Equity Research
Overhyped toxic stocks are usually susceptible to external shocks and loaded with huge amount of debt.